Hedgehog Signaling and Cancer Stem Cells in Hematopoietic Cell Malignancies

The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell malignancy in a subject by administering the Hh pathway antagonist, such as the Smo antagonist cyclopamine, in combination with the ABL-kinase antagonist imatinib.

Patents:
WO 2,010,030,948

Inventor(s): BEACHY PHILIP A [US]; REYA TANNISHTHA [US]

Type of Offer: Licensing



« More Biotech Patents

---